Neurodevelopment and mood stabilizers.

Area of Science:

• Neuroscience
• Psychiatry
• Developmental Biology

Background:

• Mood disorders and schizophrenia exhibit shared genetic susceptibilities, brain structural differences, and therapeutic responses.
• Aberrant neurodevelopment is implicated in schizophrenia; its role in mood disorders, particularly adult neurogenesis, is under investigation.
• Common mood stabilizers (lithium, valproic acid, carbamazepine) are teratogenic, impacting animal development and neuronal morphology.

Purpose of the Study:

• To explore the potential role of neurodevelopmental changes in the origins of mood disorders.
• To investigate the molecular mechanisms underlying mood stabilizer actions.
• To determine if glycogen synthase kinase-3 (GSK-3) or inositol signaling pathways are involved in bipolar disorder.

Main Methods:

• Review of existing literature on mood disorders, schizophrenia, neurodevelopment, and mood stabilizer mechanisms.
• Analysis of studies on the effects of lithium, valproic acid (VPA), and carbamazepine on cell development and neuronal morphology.
• Examination of research on GSK-3, inositol signaling, histone deacetylase (HDAC), prolyl oligopeptidase (PO), and sodium myo-inositol transporter (SMIT).

Main Results:

• Lithium inhibits GSK-3 and inositol signaling pathways.
• VPA up-regulates gene expression via HDAC inhibition and reduces GSK-3 activity; its effects vary by cell type.
• Carbamazepine does not affect GSK-3 but suppresses inositol signaling, as do lithium and VPA.

Conclusions:

• Mood stabilizers influence fundamental cellular processes, including cell development and neuronal morphology, suggesting a neurodevelopmental basis for mood disorders.
• Both GSK-3 and inositol signaling are potential molecular targets for mood stabilizers, but their specific roles in bipolar disorder etiology require further elucidation.
• Understanding these molecular pathways may lead to novel therapeutic strategies for mood disorders.